

## Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie (47)

### Impfung gegen Malaria: Die Lösung eines ganz alten Problems?

#### Literatur

- 1 WHO Team Global Malaria Programme. World Malaria Report 2021. ISBN: 978 92 4 004049 6.
- 2 [https://www.rki.de/DE/Content/Infekt/SurvStat/survstat\\_node.html](https://www.rki.de/DE/Content/Infekt/SurvStat/survstat_node.html)
- 3 <https://www.dtg.org/index.php/empfehlungen-und-leitlinien/empfehlungen/malaria.html>
- 4 Maher B. Malaria: the end of the beginning. *Nature* 2008; 451: 1042-1046. doi: 10.1038/4511042a. PMID: 18305518.
- 5 Metzger WG, Sulyok Z, Theurer A, Köhler C. Development of malaria vaccines-state of the art. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2020; 63: 45-55. doi: 10.1007/s00103-019-03070-1. PMID: 31828371. PMID: PMC7223738.
- 6 <https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk>
- 7 Cohen, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. *Hum Vaccin* 2010; 6: 90-96. doi: 10.4161/hv.6.1.9677. PMID: 19806009.
- 8 RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, Soulanoudjingar SS et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N Engl J Med* 2011; 365: 1863-1875. doi: 10.1056/NEJMoa1102287. PMID: 22007715.
- 9 RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *Lancet* 2015; 386: 31-45. doi: 10.1016/S0140-6736(15)60721-8. PMID: 25913272. PMID: PMC5626001.
- 10 Olotu A, Fegan G, Wambua J et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. *N Engl J Med* 2013; 368: 1111-1120. doi: 10.1056/NEJMoa1207564. PMID: 23514288. PMID: PMC5156295.
- 11 Olotu A, Fegan G, Wambua J et al. Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children. *N Engl J Med* 2016; 374: 2519-2529. doi: 10.1056/NEJMoa1515257. PMID: 27355532. PMID: PMC4962898.
- 12 Laurens MB. Novel malaria vaccines. *Hum Vaccin Immunother* 2021; 17: 4549-4552. doi: 10.1080/21645515.2021.1947762. PMID: 34347570. PMID: PMC8827625.
- 13 Mwakingwe-Omari M, Healy SA, Lane J, et al. Two chemically attenuated PfSPZ malaria vaccines induce sterile hepatic immunity. *Nature* 2021; 595: 289-294. doi: 10.1038/s41586-021-03684-z. PMID: 34194041.
- 14 Dattoo MS, Natama MH, Somé A et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. *Lancet* 2021; 397: 1809-1818. doi: 10.1016/S0140-6736(21)00943-0. PMID: 33964223. PMID: PMC8121760.
- 15 Mallory KL, Taylor JA, Zou X et al. Messenger RNA expressing PFCSP induces functional, protective immune responses against malaria in mice. *NPJ Vaccines* 2021; 6: 84. doi: 10.1038/s41541-021-00345-0. PMID: 34145286. PMID: PMC8213722.
- 16 Löscher T, Alberer M, Herbinger KH. Fever in travelers and migrants from the tropics. *MMW Fortschr Med* 2018; 160: 44-54. doi: 10.1007/s15006-018-0026-y. PMID: 30350043. PMID: PMC7100522.
- 17 Paquet D, Jung L, Trawinski H, Wendt S, Lübbert C. Fever in the returning traveler. *Dtsch Arztebl Int* 2022; 119: 400-407. doi: 10.3238/arztebl.m2022.0182. PMID: 35469592.